Revision as of 11:41, 1 March 2018 edit 81.28.196.10 (talk) No edit summary ← Previous edit		Revision as of 11:46, 1 March 2018 edit undo 81.28.196.10 (talk) No edit summary Next edit →
Line 32: ===Lutathera=== The company's lead product is LUTATHERA, a [[lutetium~~-177~~ ~~(Lu-~~177) dotatate]] labeled [[DOTA-TATE\|somatostatin analogue peptide]], a theragnostic cancer product being developed to treat certain gastro-entero [[pancreatic]] [[neuroendocrine tumors]] ([[GEP-NET]]s). It selectively targets over-expressed somatostatin receptors while also giving off gamma emissions to allow physicians to visualize where in the body both the drug and the tumor are. It was approved by the FDA in January 2018 for GEP-NET.<ref>[https://www.healio.com/hematology-oncology/gastrointestinal-cancer/news/online/%7B5e89833e-97c3-4a91-a2c8-88231a517b78%7D/fda-approves-lutathera-for-gastroenteropancreatic-neuroendocrine-tumors ''FDA approves Lutathera for gastroenteropancreatic neuroendocrine tumors'' Jan 2018]</ref>

Advanced Accelerator Applications: Difference between revisions